CLBIO Stock Overview
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Corline Biomedical AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr10.20 |
| 52 Week High | kr18.15 |
| 52 Week Low | kr9.64 |
| Beta | 0.50 |
| 1 Month Change | -5.99% |
| 3 Month Change | -24.44% |
| 1 Year Change | -29.66% |
| 3 Year Change | -6.42% |
| 5 Year Change | -45.01% |
| Change since IPO | -0.49% |
Recent News & Updates
Recent updates
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Shareholder Returns
| CLBIO | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 1.0% | -0.1% | 0.5% |
| 1Y | -29.7% | 60.0% | 18.6% |
Return vs Industry: CLBIO underperformed the Swedish Pharmaceuticals industry which returned 60.9% over the past year.
Return vs Market: CLBIO underperformed the Swedish Market which returned 16% over the past year.
Price Volatility
| CLBIO volatility | |
|---|---|
| CLBIO Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CLBIO's share price has been volatile over the past 3 months.
Volatility Over Time: CLBIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 13 | Henrik Nittmar | www.corline.se |
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.
Corline Biomedical AB Fundamentals Summary
| CLBIO fundamental statistics | |
|---|---|
| Market cap | kr219.21m |
| Earnings (TTM) | -kr4.50m |
| Revenue (TTM) | kr30.96m |
7.1x
P/S Ratio-48.7x
P/E RatioIs CLBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLBIO income statement (TTM) | |
|---|---|
| Revenue | kr30.96m |
| Cost of Revenue | kr6.10m |
| Gross Profit | kr24.85m |
| Other Expenses | kr29.35m |
| Earnings | -kr4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 80.29% |
| Net Profit Margin | -14.53% |
| Debt/Equity Ratio | 0% |
How did CLBIO perform over the long term?
See historical performance and comparison